A novel spray-applied treatment of allogeneic cells shows promise for persistent leg ulcers.
To test the safety and efficacy of a new treatment for persistent venous leg ulcers, investigators conducted a randomized, placebo-controlled, multicenter, manufacturer-supported trial of a novel cell therapy (HP802-247). This agent is a mixture of cryopreserved, allogeneic, growth-arrested fibroblasts and keratinocytes derived from neonatal foreskin; the cells are thawed and delivered to the ulcer surface in a fibrin spray.
The 227 patients, who had at least one persistent ulcer with a wound area of 2 to 12 square centimeters, were divided into five groups of 40 to 50 patients each. One group received vehicle alone and four experimental groups received one of two different concentrations of cells, delivered either every 7 or every 14 days. …
Reviewing Author
DisclosuresConsultant / Advisory boardAmway
Editorial boards JAMA Dermatology; Dermatologic Surgery; Journal of Cosmetic Dermatology; Lasers in Medical Science; Skin Therapy Letter
Leadership positions in professional societies American Academy of Dermatology (Chair, Health Care Finance Committee); American College of Mohs Surgery (Board of Directors); American Society for Dermatologic Surgery (Board of Directors)
DisclosuresConsultant / Advisory boardAmway
Editorial boards JAMA Dermatology; Dermatologic Surgery; Journal of Cosmetic Dermatology; Lasers in Medical Science; Skin Therapy Letter
Leadership positions in professional societies American Academy of Dermatology (Chair, Health Care Finance Committee); American College of Mohs Surgery (Board of Directors); American Society for Dermatologic Surgery (Board of Directors)